Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Hoth Therapeutics Inc (HOTH)

Hoth Therapeutics Inc (HOTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,824
  • Shares Outstanding, K 15,514
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,190 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 0.56
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +322,358.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7508 +35.86%
on 02/04/26
1.1300 -9.73%
on 01/21/26
-0.0300 (-2.86%)
since 01/13/26
3-Month
0.7508 +35.86%
on 02/04/26
1.2700 -19.69%
on 12/03/25
-0.1600 (-13.56%)
since 11/13/25
52-Week
0.6600 +54.55%
on 04/08/25
2.1150 -51.77%
on 09/23/25
-0.0500 (-4.67%)
since 02/13/25

Most Recent Stories

More News
Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases

Patent Covers Combination of FC Epsilon RI-Beta Exon Skipping and MS4A6A Modulation — Strengthening Hoth's Immunology IP Portfolio

HOTH : 1.0200 (+4.08%)
Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model

In a head-to-head preclinical comparison, HT-VA co-developed with the United States Veterans Administration GDNF demonstrated superior efficacy compared with semaglutide (the active ingredient in Wegovy®️...

HOTH : 1.0200 (+4.08%)
Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets

NEW YORK , Feb. 5, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH),  a clinical-stage biopharmaceutical company focused on advancing innovative therapies for cancer patients with...

HOTH : 1.0200 (+4.08%)
Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients

Primary endpoint ARIGA improved by ~50% from baseline by Week 6, with all evaluable patients reaching low-severity disease; additional endpoints demonstrated ~34% improvement in oncology toxicity (CTCAE)...

HOTH : 1.0200 (+4.08%)
Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position

Chinese Patent Approved Covering HT-KIT Technology Designed to Induce Cancer Cell Apoptosis, Expanding Protection in One of the World's Largest Oncology Markets

HOTH : 1.0200 (+4.08%)
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation

Positive CTIS Conclusion Positions Company for Near-Term Clinical Trial Initiation in Cancer Patients

HOTH : 1.0200 (+4.08%)
Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform

NEW YORK , Jan. 2, 2026 /PRNewswire/ -- Hoth Therapeutics  (NASDAQ: HOTH) , a clinical-stage biopharmaceutical company developing innovative therapies for underserved medical needs,...

HOTH : 1.0200 (+4.08%)
Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program

NEW YORK , Dec. 3, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) , a patient-focused clinical-stage biopharmaceutical company, today issued a comprehensive update on its therapeutic...

HOTH : 1.0200 (+4.08%)
Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025

NobleCon is the preeminent showcase of small and microcap companies

HOTH : 1.0200 (+4.08%)
Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics today announced that it...

HOTH : 1.0200 (+4.08%)

Business Summary

Hoth Therapeutics Inc. is a development stage biopharmaceutical company. It focused on therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. The company's BioLexa(TM) Platform is a proprietary, patented drug compound platform. Hoth Therapeutics Inc. is...

See More

Key Turning Points

3rd Resistance Point 1.1664
2nd Resistance Point 1.1132
1st Resistance Point 1.0666
Last Price 1.0200
1st Support Level 0.9668
2nd Support Level 0.9136
3rd Support Level 0.8670

See More

52-Week High 2.1150
Fibonacci 61.8% 1.5592
Fibonacci 50% 1.3875
Fibonacci 38.2% 1.2158
Last Price 1.0200
52-Week Low 0.6600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar